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THE recognition of antigen is the first step in matura-tion of effector T lymphocytes. Gromo et al have 
shown that antigen can trigger a precursor T lymphocyte to 
respond to additional signals necessary to induce full 
functional maturation.1.2 Using minimal signals, such as 
MoAbs to CD2 receptor or MoAbs directed against CD28, 
they have demonstrated that precursor cytotoxic T lym-
phocytes (pTcs) can differentiate into pre-effector cyto-
toxic cells (peTcs). Following the addition of recombinant 
IL-2 (rIL-2) or IFN-y, peTcs will acquire cytolytic 
activity. 1,2 Likewise, stimulation with the calcium (Ca2+) 
ionophore A23187 drives pTcs into the peTc stage, and 
rIL-2 induces peTcs to become effector cytolytic cells 
(eTcs), I 
CyA, a T cell-specific immunosuppressive drug, inhibits 
the generation of effector cells by blocking IL-2 and, to a 
lesser degree, IL-J production (reviewed in reference 3), A 
new immunosuppressive drug, FK 506, has properties 
similar to CyA, but it is 100 to 400 times more potent.4-9 
The strong in vitro inhibitory effect of FK 506 can be 
demonstrated in primary mixed lymphocyte cultures 
(MLRs) and secondary proliferation of alloreactive T cells 
propagated from organ transplant biopsies.6-9 
Cy A and FK 506 appear to inhibit the transcription of 
early T cell activation genes, including those coding for 
IL-2, IL-3, and IFN_y,3,IO,11 These drugs do not affect the 
proliferation of activated T cells in the presence of IL-2 or 
the cytolytic effector function. 7 ,8 
Little is known of the effect of these drugs on the stages 
of cytolytic T lymphocyte (CTL) generation. This study 
was designed to evaluate the effects of these drugs on the 
stepwise activation, proliferation, and maturation of CTLs 
induced by A23J87 and rIL-2. 
MATERIALS AND METHODS 
Cells 
PBLs were isolated by Ficoll-Hypaque density gradient centrifu-
gation of heparinized blood from normal healthy donors. 7 Cells 
were resuspended in tissue culture medium (TCM) consisting of 
RPMI 1640 supplemented with 25 mmoliL Hepes buffer and 100 
U/ml gentamicin, with 10% normal AB human serum. Viability of 
isolated PBLs was routinely 99% as determined by staining with 
1% eosin. 
Drug Sources 
CyA was obtained from Sandoz (Basel, Switzerland) and was 
dissolved in ethanol (1 mg/ml), FK 506 was kindly provided by 
Fujisawa Pharmaceuticals (Osaka, Japan) as a crystalline powder 
and was dissolved in methanol (1 mg/ml). rIL-2 (Sandoz) was 
obtained as a stock solution of 100,000 U/ml. A23187 (Sigma, St 
Louis, MO) was diluted in ethanol (I mg/ml), Phytohemglutinin 
(PHAJ, concanavalin A (Con A) and phorbol myristate acetate 
(PMA) were obtained from Sigma and used at 1%, 50 ~mlI and 
0.1 lLg/ml, respectively, 
Proliferation Under Different Activation Conditions 
Triplicate cultures ofPBL were set up in TCM at 2 x 106/ml in the 
presence of A23187 (0.75-1.0 lLg/ml), PHA (1%), or PMA (0.1 
lLg/ml) in a volume of 200 ILl for 3 days. Proliferation was assessed 
by 3H-thymidine uptake during the last 20 hours of incubation, 
harvested onto fiber glass paper, and counted in a liquid scintilla-
tion counter (LKB). 
Dose Effects of FK 506 and CyA on 
Lymphocyte Proliferation 
The inhibitory effects of CyA and FK 506 on the lymphocyte 
response to different activation conditions were assessed, The 
concentrations used were I and 0.1 ng/ml of FK 506 and 100 and 
10 ng/ml of CyA. The results were expressed as the percent of 
inhibition of the proliferative response using the following for-
mula: 
% inhibition = (I - cpm with drug/cpm without drug) x 100 
51 Cr Release 
Cytotoxicity was determined in a standard LDCC assay as previ-
ously described. 2 LDCC was performed in the presence of Con A 
at 50 lLg/ml. The effector to target ratio was 20: I, The percentage 
of lysis was calculated using the following formula: 
% lysis = (experimental - background/total - background) x 100 
The effectors were harvested at day 3 after initiation of the 
culture for the first phase of activation, and after an additional 2 
days of culture in the presence of 100 U/ml of rIL-2 for the second 
phase of activation, The RPM I cell line was used as the target in 
LDCC assays, 
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Table 1. Inhibitory Effects of FK 506 and CyA on the Response Induced by A23187, PHA, and PMA 
Proliferation' FK506 
Mitogen (cpm ± SD) (1 ng/ml) 
A23187 (0.75 JL!j/ml) 19,979 ± 2,240 98 
A23187 (1 IL9/ml) 34,077 ± 6,181 95 
PHA (1%) 180,465 ± 9,558 53 
PMA (0.1 JL!j/ml) 104,806 ± 8,826 
'Background proliferation: 286 ± 124 cpm. 
IL-2 Production 
IL-2 was measured in a bioassay using an IL-2-dependent T cell 
line, CTLL_2.12 Supernatants were collected after 24 hours under 
each activation condition in the presence or absence of immuno-
suppressive drugs. CTLL-2 cells were plated at 104/well and 100 
ILl/well of supernatant in a 96-well flat-bottomed plate. Triplicate 
cultures were incubated for 24 hours and pulsed with 1 ILCi/well of 
3H-thymidine during the last 8 hours. rIL-2 was used as a positive 
control. 
RESULTS 
Effects of FK 506 and CyA on the Proliferative Responses of 
Human Peripheral Blood Lymphocytes 
The proliferative response of PBL induced by A23187 was 
significant but less than PHA or PMA stimulation (Table 
1). FK 506 and Cy A inhibited over 90% of the response to 
A23187 at doses of 1 ng/ml and 100 ng/ml, respectively. 
PHA-induced proliferation of PBL was less sensitive than 
A23187-stimulated proliferative response, and at doses of I 
ng/ml FK 506 or 100 ng/ml CyA, only 50% inhibition was 
achieved. Furthermore, the mitogenic response of human 
PBL to PMA was completely resistant to FK 506 or Cy A 
(Table 1). These results indicated that FK 506 significantly 
inhibited proliferative responses to A23187 and PHA, and 
this effect was observed at doses l00-fold lower than with 
CyA. 
Effect of FK 506 and CyA on IL-2 Secretion 
The secretion of IL-2 at 24 hours after stimulation with 
A23187 was inhibited by FK 506 (1 ng/ml) and CyA (100 
ng/ml) , whereas PMA-induced IL-2 release was not af-
fected (Table 2). IL-2 release following A23187 stimulation 
was more inhibited by low doses of FK 506 and Cy A (0.1 
ng/ml and 10 ng/ml, respectively) than was PH A-induced 
IL-2 release. 
Percent Inhibition of the Proliferative Responses 
FK506 eVA eVA 
(0.1 nglml) (100 nglml) (10 nglml) 
67 99 78 
33 97 51 
28 48 16 
3 2 
Effects of FK 506 and CyA on the Maturation of CytotoxiC 
TCeils 
A23187-activated cells had no detectable LDCC activity 
(Table 3), whereas PHA activation induced a significant 
LDCC response (24%). PMA-stimulated cells exhibited 
intermediate LDCC activity (12%). On addition of rIL-2 
(100 D/ml) for 2 days, all cultures demonstrated significant 
cytolytic activity (Table 3). Addition of FK 506 and CyA 
during this second step did not affect the development of 
cytotoxic activity in A23187-stimulated cells nor did it 
inhibit the augmented response of PHA-activated cells. 
Thus, neither FK 506 nor Cy A influenced the IL-2-induced 
conversion of peTcs to CTLs. 
DISCUSSION 
The present study demonstrates that FK 506 and CyA 
significantly inhibit the proliferation and IL-2 release of 
A23187-stimulated cells but have no effect on the matura-
tion of peTc to active CTL when help is provided in the 
form of rIL-2. Gromo et al have shown that the induction 
of CTL involves a series of events including proliferation 
and differentiation. 1,2 To study the effect of immunosup-
pressive drugs on the various stages, we employed the 
stepwise approach using minimal signals that do not, by 
themselves, result in full maturation to effector cytolytic 
cells. An example of a minimal signal associated with 
activation along alternative pathways is A23187-induced 
stimulation of pTcs to peTcs. These peTcs can proliferate 
but do not exhibit CTL activity. 
A23187-induced proliferation is IL-2-dependent, and 
low doses of FK 506 or Cy A can fully suppress the 
proliferation and IL-2 release of these cell cultures. The 
concept of IL-2 dependence of A23187 induction of T cell 
proliferation is controversial. Recently, Chatila et al dem-
Table 2. Inhibitory Effects of CyA and FK 506 on IL-2 Release by Activated T Lymphocytes 
Percent Inhibition of IL-2 Release 
CTLL-2' 
Proliferation FK506 FK506 eVA eyA 
Mitogen (cpm ± SD) (1 ng/ml) (0.1 nglml) (100 nglml) (10 ng/ml) 
A23187 (0.75 JL!j/ml) 21,065 ± 4,272 99 88 99 96 
A23187 (1 JL!j/ml) 73,092 ± 1,148 99 26 99 51 
PHA (1%) 31,009 ± 1,199 67 6 70 23 
PMA (0.1 JL!j/ml) 38,598 ± 715 3 2 
'3H·thymidine incorporation of the IL-2-dependent CTLL-2 cell line in the presence of supernatants obtained 24 hours after stimulation in different culture conditions. 
Background proliferation: 67 ± 18 cpm. Proliferation in the presence of 100 U/mIIL·2: 110,358 ± 6,822 cpm. 
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Table 3. Cytotoxic Activity of PBl Stimulated With A23187, 
PHA,and PMA 
%CML' 
Mitogen (No Drugs) 
A23187 (0.75 J.L9/ml) 3±1 
A23187 (1 J.L9/ml) 3 ± 1 
PHA (1%) 24 ± 3 
PMA (100 ng/ml) 12 ± 1 
'The effector to target ratio was 20:1. 
nit denotes not tested. 
% CML' After Addition of 
Exogenous IL-2 (100 U/ml) 
FK506 CyA 
No Drugs (1 ng/ml) (100 ng/ml) 
56 ± 1 60 ± 3 67 ± 3 
64 ± 6 65 ± 8 67 ± 3 
43 ± 1 36 ± 3 48 ± 2 
39 ± 2 nit nit 
onstrated that the Ca2 + ionophore, A23187, is a monocyte-
dependent T cell mitogen associated with IL-2 production 
and that it is partially inhibited by anti-IL-2 receptor 
MoAb. 13 On the other hand, several laboratories have 
previously reported IL-2-independent induction of T cell 
proliferation by A23187. 14.15 The discrepancies among 
various laboratories may be related to the experimental 
conditions and, in particular, to the choice of Ca2 + iono-
phores. 
Confirming previous reports,I ,2,15 we have observed 
that A23187 alone cannot drive the pTc to an eTc, Cells 
responding to an antigen or anti-CD3 MoAb release IL-2 
and express cytotoxic activity, whereas those stimulated 
by the minimal signals do not produce detectable IL-2 and 
fail to exhibit cytolytic activity, 2 On the other hand, our 
findings suggest that A23187-stimulated cells do not ma-
ture to CTLs in spite of detectable IL-2 release. It is 
possible that the level of IL-2 accumulated in A23187 
cultures was not enough to provide the second signal, or 
that A23187-stimulated cells exhibited a low affinity to the 
IL-2 released in these cultures. IL-2 production of A23187 
and PHA-stimulated cells was in the same range. PMA 
activation induced comparable levels ofIL-2, also without 
inducing significant CTL activity. These findings suggest 
that under our experimental conditions, A23187 and PMA 
may deliver more than one type of signal to T cells. Gromo 
et al proposed at least three categories of signals in T cell 
activation. I The "minimal signal" may drive the differen-
tiation of pTcs to peTcs, the "inhibitory signal" appar-
ently prevents cells from proceeding further in the matu-
ration pathway, and the' 'bi-functional signals" can deliver 
both a positive and a negative signal. A23187 stimulation 
induces maturation of pTcs to peTcs, but prevents the 
peTcs from progressing into eTcs. Likewise, PMA and 
other molecules may also deliver more than one type of 
signal, depending on dose, time of exposure, and other 
factors. 16 
Lymphocyte activation by A23187 was more sensitive to 
inhibition by FK 506 and CyA than was activation by 
PHA. Kay et al have also reported that A23187 activation 
of pig lymphocytes is more sensitive to CyA inhibition 
than Con A stimulation. 17 
In vitro studies with Ca2+ ionophore and phorbol esters 
have shown that increased concentrations of Ca2+ and 
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Fig 1. Effects of FK 506 and CyA on proliferation and functional 
maturation of human cytotoxic T cells. 
activation of protein kinase C appear to be required for the 
full activation of T cells. 3 Cy A interferes with certain 
pathways that stimulate gene expression in T cells induced 
by Ca2 + but not with those stimulated by protein kinase 
C. 3 Likewise, FK 506 affects A23187 activation events but 
has no effect on PMA-induced activation and IL-2 gene 
expression. 
Another response resistant to immunosuppressive drugs 
FK 506 and eyA is the IL-2-driven proliferation of acti-
vated T cells.7-9 Similarly, IL-2-driven maturation of 
peTcs is not inhibited by FK 506 or CyA. Thus, these 
drugs affect only the pTc ~ peTc stage but not the peTc ~ 
eTc stage (Fig I). Recently, two groups have shown that 
Cy A and FK 506 bind to different proteins (cyclophilin and 
FK 506 binding protein) that share a common enzymatic 
property.18,19 Both proteins have isomerase activity that 
may be important in Ca2+ -dependent intracellular signal-
ling events in T cell activation. 18,19 
FK 506 induces considerable prolongation of allograft 
survival in various species: cardiac transplants in rats, 
renal and liver allografts in dogs, and kidney allografts in 
baboons. 2o-23 Delayed treatment with FK 506 (ie, on days 
5, 6, and 7 posttransplant) was also shown to be effective 
in preventing allograft failure in several experimental 
models. 22 ,23 The in vivo findings do not contradict our in 
'::,fI.) otJservations. Allograft rejection is a complex pro-
cess in which lymphokines and activated effector cells all 
play important roles. FK 506 is a potent drug that effi-
ciently suppresses lymphokine production, thus shutting 
off ongoing allograft rejection. FK 506 is currently being 
used at our institution in phase I clinical trials to treat 
"rescue" patients who have failed to respond to conven-
tional therapy24 and as the primary immunosuppressive 
agent in liver transplantation.25 
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